A study has revealed why some patients don't respond to immune checkpoint blockade (ICB) therapy for solid cancer tumors and identifies a new combination treatment. Publishing in Nature Immunology, ...

Across the immunity cycle, NPs can co-deliver tumor antigens and adjuvants to DCs, enhance major histocompatibility complex class I (MHC-I)-mediated cross-presentation, and promote cytotoxic T ...

A new Phase I clinical trial provides proof of concept for a potential therapy for treatment-resistant cancers, particularly ...

Some patients treated with immunotherapy may develop lifelong endocrine conditions requiring ongoing hormone replacement, insulin therapy and long-term monitoring, according to Vi ...

Immune system activation and activity is regulated through stimulatory or inhibitory ligand-receptor interactions collectively termed immune checkpoints. 1 Stimulatory interactions give the immune ...

Patients being treated with immune checkpoint inhibitors may be at higher risk for developing uveitis, according to a speaker ...

Although cancer immunotherapy has transformed treatment by harnessing the immune system to eliminate tumors, only a small ...

Checkpoint inhibitors are a groundbreaking class of cancer treatment, but they come with two frustrating challenges. In some cases, tumors show no initial response, rendering the therapy ineffective ...

Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering ...